Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The review concluded that daily primaquine doses between 0.25 mg/kg and 0.5 mg/kg were well tolerated in patients with greater than 30% G6PD activity, and that all patients with P. vivax malaria experience infection-induced haemolysis, irrespective of primaquine administration.”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [23]
In the citing paper
“A plausible explanation could be the high predominance of G6PD-normal individuals with a very low risk for serious adverse effects [23].”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [23]
In the citing paper
“The review concluded that daily primaquine doses between 0.25 mg/kg and 0.5 mg/kg were well tolerated in patients with greater than 30% G6PD activity, and that all patients with P. vivax malaria experience infection-induced haemolysis, irrespective of primaquine administration.”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [23]
In the citing paper
“The haematological changes observed in the study, with a very low prevalence of clinically relevant outcomes defined as > 25% haemoglobin reduction to below 8 g/dL or the composite measure of haemoglobin changes, are consistent with the findings from an individual patient data meta-analysis that evaluated primaquine doses and their associated risk of haemolysis [23].”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [23]
In the citing paper
“Recent multi-country pooled analyses have demonstrated that a high total dose of primaquine (7 mg/kg) provides substantially greater protection against relapse compared with the low-dose (3.5 mg/kg total dose) regimen [8, 9]”
From Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battle, K. E., Lucas, T. C. D., Nguyen, M., Howes, R. E., Nandi, A. K., Twohig, K. A., Pfeffer, D. A., Cameron, E., Rao, P. C., Casey, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31096-7 · Cited by 409
Watson, J., Taylor, W. R. J., Bancone, G., Chu, C. S., Jittamala, P., & White, N. J. (2018) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006440 · Cited by 77 · cited 1×
“As such, our analysis did not require additional ethics approval according to the guidelines of the Oxford Central University Research Ethics Committee.”
MethodSelf-citation
Research works printed but not linked: 38
- Douglas, 2014, Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia, BMC Med, 12, 217, 10.1186/s12916-014-0217-z · DOI
- Chu, 2021, The prevention and treatment of Plasmodium vivax malaria, PLoS Med, 18, 10.1371/journal.pmed.1003561 · DOI · Paper page
- Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map, PLoS Med, 9, 10.1371/journal.pmed.1001339 · DOI · Paper page
- Gómez-Manzo, 2016, Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world, Int J Mol Sci, 17, 10.3390/ijms17122069 · DOI · Paper page
- Domingo, 2019, Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities, Int Health, 11, 7, 10.1093/inthealth/ihy060 · DOI · Paper page
- Thriemer, 2017, Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group, Malar J, 16, 141, 10.1186/s12936-017-1784-1 · DOI · Paper page
- Commons, 2017, The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials, Int J Parasitol Drugs Drug Resist, 7, 181, 10.1016/j.ijpddr.2017.03.003 · DOI
- Commons, 2019, The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis, BMC Med, 17, 151, 10.1186/s12916-019-1386-6 · DOI · Paper page
- Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
- White, 2018, Anaemia and malaria, Malar J, 17, 371, 10.1186/s12936-018-2509-9 · DOI · Paper page
- Lee, 2008, The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria, Malar J, 7, 149, 10.1186/1475-2875-7-149 · DOI
- Hasugian, 2007, Dihydroartemisinin–piperaquine versus artesunate–amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria, Clin Infect Dis, 44, 1067, 10.1086/512677 · DOI · Paper page
- Pukrittayakamee, 2010, A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand, Am J Trop Med Hyg, 82, 542, 10.4269/ajtmh.2010.09-0428 · doi:10.4269/ajtmh.2010.09-0428
- Barber, 2013, A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy, Clin Infect Dis, 56, 383, 10.1093/cid/cis902 · DOI · Paper page
- Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study, Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
- Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia, BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
- Ley, 2016, G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study, PLoS One, 11, 10.1371/journal.pone.0154015 · DOI
- Saravu, 2016, Therapeutic assessment of chloroquine–primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in southwestern India, PLoS One, 11, 10.1371/journal.pone.0157666 · DOI · Paper page
- Abreha, 2017, Comparison of artemether–lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial, PLoS Med, 14, 10.1371/journal.pmed.1002299 · DOI · Paper page
- Awab, 2017, Chloroquine–primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial, Am J Trop Med Hyg, 97, 1782, 10.4269/ajtmh.17-0290 · DOI · Paper page
- Chu, 2018, Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine–primaquine in Plasmodium vivax malaria, Clin Infect Dis, 67, 1543, 10.1093/cid/ciy319 · DOI · Paper page
- Grigg, 2018, Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors of severity, Clin Infect Dis, 67, 350, 10.1093/cid/ciy065 · DOI
- Chu, 2019, Chloroquine versus dihydroartemisinin–piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria, Clin Infect Dis, 68, 1311, 10.1093/cid/ciy735 · DOI
- Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
- Ladeia-Andrade, 2019, Monitoring the efficacy of chloroquine–primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil, Antimicrob Agents Chemother, 63, e01965, 10.1128/AAC.01965-18 · DOI · Paper page
- Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
- Rijal, 2019, Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal, J Infect Dis, 220, 448, 10.1093/infdis/jiz126 · DOI · Paper page
- Edgcomb, 1950, Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report, J Natl Malar Soc, 9, 285
- Commons, 2023, Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis, Lancet Infect Dis
- Thriemer, 2021, Towards the elimination of Plasmodium vivax malaria: implementing the radical cure, PLoS Med, 18, 10.1371/journal.pmed.1003494 · DOI
- Douglas, 2013, Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study, PLoS Med, 10, 10.1371/journal.pmed.1001575 · DOI · Paper page
- Bancone, 2017, Prevalences of inherited red blood cell disorders in pregnant women of different ethnicities living along the Thailand–Myanmar border, Wellcome Open Res, 2, 72, 10.12688/wellcomeopenres.12338.1 · DOI
- Chu, 2017, Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens, PLoS Med, 14, 10.1371/journal.pmed.1002224 · DOI · Paper page
- Pal, 2019, Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient, Am J Trop Med Hyg, 100, 213, 10.4269/ajtmh.18-0612 · DOI · Paper page
- Sadhewa, 2023, A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria, Pathogens, 12, 650, 10.3390/pathogens12050650 · DOI
- Brito-Sousa, 2022, Quantitative G6PD deficiency screening in routine malaria diagnostic units in the Brazilian Amazon (SAFEPRIM): an operational mixed-methods study, Pathogens, 11, 10.3390/pathogens11111328 · DOI
- Ley, 2022, Variation in glucose-6-phosphate dehydrogenase activity following acute malaria, PLoS Negl Trop Dis, 16, 10.1371/journal.pntd.0010406 · DOI
- Pukrittayakamee, 2023, Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency, eLife, 12
Cited by
Degaga, T. S., Sime, H., Ruybal-Pesántez, S., Osborne, A., Mwaura, M., Bamboro, S. A., Mnjala, H., Mekonnen, G., Ermias, S., Fantahun, A., et al. (2026) · Malaria Journal · doi:10.1186/s12936-026-06050-4 · Cited by 1
Self-citationShifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05709-8
Self-citation
Metadata
- Authors
- Rajasekhar, M., Simpson, J. A., Ley, B., Edler, P., Chu, C. S., Abreha, T., Awab, G. R., Baird, J. K., Bancone, G., Barber, B. E., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Llanos-Cuentas, A., Pukrittayakamee, S., Rijal, K. R., Saravu, K., Sutanto, I., Taylor, W. R. J., Thriemer, K., Watson, J. A., Guerin, P. J., White, N. J., Price, R. N., Commons, R. J., Adhikari, B., Alam, M. S., Anstey, N. M., Assefa, A., Boyd, S. C., Chau, N. H., Day, N. P., Degaga, T. S., Dondorp, A. M., Ferreira, M. U., Ghimire, P., Green, J. A., Khan, W. A., Koh, G. C., Mekuria, A. H., Naadim, M. N., Nelwan, E. J., Nosten, F., Pasaribu, A. P., Price, D. J., Stepniewska, K., von Seidlein, L., William, T., Woodrow, C. J., & Woyessa, A.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 24
- Issue
- 2
- Pages
- 184-195
- ISSN
- 1473-3099
- Cited by
- 42
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Health and Medical Research Council (2017436, 2008501, 2016792, 1196068, 1194702)
- Bill & Melinda Gates Foundation
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (093956/Z/10/C, 223253/Z/21/Z)
- Capability Systems Centre
- Centers for Disease Control and Prevention
- Wellcome Trust
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(23)00431-0
- The paper
- Rajasekhar, M., Simpson, J. A., Ley, B., Edler, P., Chu, C. S., Abreha, T., Awab, G. R., Baird, J. K., Bancone, G., Barber, B. E., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Llanos-Cuentas, A., Pukrittayakamee, S., Rijal, K. R., Saravu, K., . . . Woyessa, A. (2024). Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(23)00431-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.